ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
|
ORIGINAL RESEARCH ARTICLES |
T H E Evaluation Of The Protective Effect Of Venlafaxine Against Chemotherapy Induced Neuropathy
Dr. Mehmet BATMAZOĞLUa, Dr. Türkan EVRENSELb, Dr. Osman MANAVOĞLU, bDr. Özkan KANATbDeniz SIĞIRLI,c
aNefroloji BD,Pamukkale Üniversitesi Tıp Fakültesi,Denizli bMedikal Onkoloji BD, cBiyoistatistik AD,Uludağ Üniversitesi Tıp Fakültesi, Bursa
Objective: Taxanes are widely used chemotherapeutic agents in the treatment of several malignancies including breast, non-small cell lung, ovarian and head and neck cancers. Toxicity of these agents includes bone marrow suppression (principally neutropenia), hypersensitivity reactions, cutaneous reactions, edema and neurotoxicity. Neurotoxicity develops cumulatively and is among the most important and dose limiting toxicity of these agents. The most prominent neurotoxicity is sensory neuropathy. The precise mechanism for taxane-induced neuropathy is still unknown. The taxanes are known to promote aggregation of intracellular microtubules. Abnormal aggregation of microtubules in the neuronal cells may cause this neuropathy. Recently, a novel antidepressant agent venlafaxine was reported to have a preventive role in the chemotherapy-induced neurotoxicity. In this study, we aimed to investigate the protective effect of venlafaxine against paclitaxel- and docetaxel-induced neurotoxicity while using it with paclitaxel and docetaxel.
Material and Methods: Between January 2004 and September 2004 in the Department of Oncology, School of Medicine, Uludağ University, 22 patients with solid tumors planned to receive paclitaxel or docetaxel based chemotherapy were enrolled in the study. 12 patients in group A were treated with chemotherapy alone while 10 patients in group B were treated with chemotherapy plus venlafaxine (75 mg/day). Total neuropathy scores (TNS) and pain scores (VAS) were determined for all patients before chemotherapy and after the last course of chemotherapy. Results: There was no statistically significant difference in terms of TNS and VAS scores between groups A and B. Conclusion: As a result, we decided that venlafaxine had no protective effect on neuropathy induced by taxane-dependent chemotherapy regimes.Keywords: Neurotoxicity Syndromes; paclitaxel; venlafaxine; docetaxelTurkiye Klinikleri J Med Sci 2008, 28:425-436
|
|
|
|
|
